

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/551,643-Conf. #5446
				Filing Date	July 24, 2006
				First Named Inventor	Giovanni Monteleone
				Art Unit	1635
				Examiner Name	K. Chong
				Attorney Docket Number	GIU-001
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A2*	US-6,020,464	02-01-2000	Okazaki et al.	
	A3*	US-6,747,014	06-08-2004	Teng et al.	
	A4*	US-20020147140	10-10-2002	Rosen et al.	
	A5*	US-20020061569	05-23-2002	Haselbeck et al.	
	A6*	US-20040209805	10-21-2004	Phillips et al.	
	A7*	US-20040265833	12-30-2004	Lofton-Day et al.	
	A8*	US-20060034800	02-16-2006	Sanna et al.	
	A9*	US-20070167385	07-19-2007	Monteleone	
	A10*	US-20080214483	09-04-2008	Schlingensiepen et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B3	EP-874046	10-28-1998	Biomolecular Engineering		
	B4	EP-1308459	05-07-2003	Helix Res Inst [JP] et al.		
	B5	WO-97/30065	08-21-1997	Millennium Pharm Inc.		
	B6	WO-98/53068	11-26-1998	Ludwig Inst Cancer Res		
	B7	WO-99/50296	09-06-2002	PE Corp NY US		
	B8	WO-99/60012	11-25-1999	Isis Pharmaceuticals		
	B9	WO-00/06206	02-10-2000	Millennium Pharm Inc.		
	B10	WO-01/94629	12-13-2001	Avalon Pharmaceuticals		
	B11	WO-01/57182	08-09-2001	Human Genome Sciences Inc. et al.		
	B12	WO-01/55367	08-02-2001	Human Genome Sciences Inc. et al.		
	B13	WO-02/00927	01-03-2002	Epigenomics AG		
	B14	WO-02/68579	09-06-2002	PE Corp NY US		
	B15	WO-02/12440	02-14-2002	Gene Logic [US] et al.		
	B16	WO-02/77183	10-03-2002	Elitra Pharmaceuticals et al.		
	B17	WO-02/85285	10-31-2002	Wyeth Corp et al.		
	B18	WO-03/37368	05-08-2003	Steinbrecher Andreas [DE] et al.		
	B19	WO-04/87920	10-14-2004	Giuliani Spa [IT] et al.		
	B20	WO-04/83389	09-30-2004	Exelixis Inc. et al.		
	B21	WO-04/41170	05-21-2004	Genentech Inc. et al.		
	B22	WO-04/53099	06-24-2004	Scripps Research Inst et al.		
	B23	WO-05/98041	10-20-2005	University of Florida et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/551,643-Conf. #5446
				Filing Date	July 24, 2006
				First Named Inventor	Giovanni Monteleone
				Art Unit	1635
				Examiner Name	K. Chong
Sheet	2	of	2	Attorney Docket Number	GIU-001

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B24	WO-05/77403	08-25-2005	Stryker Corp et al.		
	B25	WO-05/14011	02-17-2005	Giuliani Spa [IT] et al.		
	B26	WO-05/12875	02-10-2005	Squibb Bristol Meyers et al.		
	B27	WO-05/49642	06-02-2005	Pasteur Institute [FR] et al.		
	B28	WO-07/22642	03-01-2007	Replicor Inc.		
	B29	WO-07/120847	10-25-2007	Massachusetts Inst Technology et al.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C34	Stopa et al. "Genomic locus and promoter region of rat Smad7, an important antagonist of TGF- $\beta$ signaling" Mammalian Genome (2000), 11(2), pp. 169-176.	
	C35	Stopa et al. "Participation of Smad2, Smad3, and Smad4 in transforming growth factor $\beta$ (TGF- $\beta$ ) - induced activation of Smad7: the TGF- $\beta$ response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional regulation" J. of Biological Chemistry, (2000) 275(38), pp. 29308-29317.	
	C36	Nakao et al. "Identification of Smad7, a TGF- $\beta$ inducible antagonist of TGF- $\beta$ signaling" Nature (London) (1997) 389(6651), pp. 631-635.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

LBBC/3565793.1

Examiner Signature	/Kimberly Chong/	Date Considered	05/26/2009
-----------------------	------------------	--------------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./